Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
5 p, 1.6 MB Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial / Raggi, Paolo (Division of Cardiology and Department of Medicine, University of Alberta, Edmonton, Alberta, Canada) ; Bellasi, Antonio (Research, Innovation and Brand Reputation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy) ; Sinha, Smeeta (Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom) ; Bover, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Rodriguez, Mariano (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Ketteler, Markus (Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany) ; Bushinsky, David A. (Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA) ; Garg, Rekha (PharmaDRS, LLC, San Diego, California, USA) ; Perelló, Joan (University of the Balearic Islands, Palma, Spain) ; Gold, Alex (Department of Medicine, Stanford University, Palo Alto, California, USA) ; Chertow, Glenn M. (Department of Medicine, Stanford University, Palo Alto, California, USA) ; Universitat Autònoma de Barcelona
Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving maintenance hemodialysis. [...]
2020 - 10.1016/j.ekir.2020.09.032
Kidney International Reports, Vol. 5 (november 2020) , p. 2178-2182  
2.
9 p, 506.6 KB Trial design and baseline characteristics of CaLIPSO : a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification / Bellasi, Antonio (Research, Innovation and Brand Reputation Unit, ASST Papa Giovanni XXIII) ; Raggi, Paolo (Department of Medicine, Mazankowski Alberta Heart Institute and University of Alberta) ; Bover, Jordi (Institut d'Investigació Biomèdica Sant Pau) ; Bushinsky, David A. (Department of Medicine, University of Rochester Medical Center) ; Chertow, Glenn M. (Department of Medicine, Stanford University) ; Ketteler, Markus (Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus) ; Rodriguez, Mariano (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ; Sinha, Smeeta (Department of Renal Medicine, Salford Royal NHS Foundation Trust) ; Salcedo, Carolina (Research and Development, Sanifit Therapeutics) ; Garg, Rekha (Research and Development, Sanifit Therapeutics) ; Gold, Alex (Research and Development, Sanifit Therapeutics) ; Perelló, Joan (Research and Development, Sanifit Therapeutics) ; Universitat Autònoma de Barcelona
The objective of CaLIPSO, a Phase 2b, randomized, double-blind, placebo-controlled clinical trial, is to test the hypothesis that myo-inositol hexaphosphate (SNF472) attenuates the progression of cardiovascular calcification in patients receiving maintenance haemodialysis. [...]
2019 - 10.1093/ckj/sfz144
Clinical Kidney Journal, Vol. 14 (october 2019) , p. 366-374  

Vegeu també: autors amb noms similars
1 Gold, Andrea L.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.